CURE Pharmaceutical Holding Corp. announced successful results from its initial Pharmacokinetics (PK)/bioequivalence studies. CURE will now advance its clinical program with the objective of U.S. Food and Drug Administration (FDA) approval. CUREfilm Blue™ utilizes the Company’s patented and proprietary fast-dissolving drug delivery platform, known as CUREfilm™, to deliver the active pharmaceutical ingredient (API) sildenafil citrate. By innovating beyond the traditional pharmaceutical delivery of pills and solutions, CURE is advancing this uniquely discrete, convenient and portable oral film product for achieving a better patient experience.